Clinically Isolated Syndrome Clinical Trial
— CIS-COHORTOfficial title:
Clinically Isolated Syndrome and Newly Diagnosed Multiple Sclerosis: Diagnostic, Prognostic and Therapy - Response Markers - a Prospective Observational Study (Berlin CIS-COHORT)
A majority of patients with multiple sclerosis initially presents with a single demyelinating event, e.g. in the optic nerves, brain, brainstem or spinal cord, referred to as a clinically isolated syndrome (CIS). Not all patients with CIS get a relapse and develop multiple sclerosis but in those patients who do, irreversible damage of the central nervous system, e.g. axonal damage, is already detectable in that early stage of disease. Early initiation of immunomodulatory therapy is crucial for patients with clinically isolated syndrome who are at high risk for the development of multiple sclerosis. Vice versa identification of low risk patients could help to avoid an unnecessary therapy. In this prospective observational study we want to follow up patients with CIS and early multiple sclerosis over a period of four years and obtain clinical, laboratory and MRI - data in order to identify risk factors for relapses, prognostic factors and therapy response markers.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 2017 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - age > 18 years - signed informed consent - clinically isolated syndrome within the last 6 months - diagnosis of multiple sclerosis within the last two years Exclusion Criteria: - eye disease that could interfere with OCT (e.g. glaucoma, diabetic retinopathy) - secondary progressive multiple sclerosis - pregnancy - contraindications for MRI, e.g. pacemaker, metal implants, allergy against gadolinium - alcohol or drug abuse |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Germany | Department of Neurology, Charité - Universitätsmedizin Berlin | Berlin | |
Germany | NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin | Berlin |
Lead Sponsor | Collaborator |
---|---|
Charite University, Berlin, Germany |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | time (in days) until relapse during the observation period of four years | 48 months | No | |
Secondary | MRI - parameters: number and volume of T2 and gadolinium enhancing lesions, analysis of lesion patterns (spinal und cerebral MRI) | 48 months | No | |
Secondary | biomarkers: RNA, microRNA, DNA, proteins, enzymes, autoantibodies, antiviral antibodies, virus DNA, Vitamin D and lipids in serum, plasma, peripheral cells, urine, saliva and CSF | 48 months | No | |
Secondary | Optical Coherence Tomography (OCT): thickness of the retinal nerve fibre layer (RNFL) or total macular volume (TMV) | 48 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT03979391 -
Isoelectric Focusing of Tears in Children With Radiologically Isolated or Clinically Isolated Syndrome
|
N/A | |
Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
Recruiting |
NCT03541226 -
Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS)
|
||
Active, not recruiting |
NCT04998851 -
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
|
Phase 4 | |
Recruiting |
NCT05277740 -
Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
|
||
Recruiting |
NCT03004079 -
Clinical Importance of Glucose Regulation in Relapsing MS
|
||
Completed |
NCT02043964 -
Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion
|
N/A | |
Completed |
NCT00287079 -
A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome
|
Phase 3 | |
Terminated |
NCT04599023 -
Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System
|
||
Completed |
NCT01728922 -
Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT01737372 -
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
|
N/A | |
Terminated |
NCT00595920 -
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT05204459 -
MS-ResearchBiomarkerS
|
||
Completed |
NCT04705610 -
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography
|
N/A | |
Recruiting |
NCT03610139 -
Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients
|
N/A | |
Active, not recruiting |
NCT04009005 -
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
|
N/A | |
Not yet recruiting |
NCT06280755 -
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
|
||
Completed |
NCT03872583 -
Understanding Magnetic Resonance Imaging in Multiple Sclerosis
|
N/A | |
Not yet recruiting |
NCT06274671 -
Glymphatic MRI in Clinically Isolated Syndrome
|